AU2009305113B2 - Dengue virus neutralizing antibodies and uses thereof - Google Patents

Dengue virus neutralizing antibodies and uses thereof Download PDF

Info

Publication number
AU2009305113B2
AU2009305113B2 AU2009305113A AU2009305113A AU2009305113B2 AU 2009305113 B2 AU2009305113 B2 AU 2009305113B2 AU 2009305113 A AU2009305113 A AU 2009305113A AU 2009305113 A AU2009305113 A AU 2009305113A AU 2009305113 B2 AU2009305113 B2 AU 2009305113B2
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
acid sequence
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009305113A
Other languages
English (en)
Other versions
AU2009305113A1 (en
Inventor
Antonio Lanzavecchia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Original Assignee
Inst Res Biomedicine
Institute for Research in Biomedicine IRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Res Biomedicine, Institute for Research in Biomedicine IRB filed Critical Inst Res Biomedicine
Publication of AU2009305113A1 publication Critical patent/AU2009305113A1/en
Priority to AU2013202434A priority Critical patent/AU2013202434B2/en
Application granted granted Critical
Publication of AU2009305113B2 publication Critical patent/AU2009305113B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C07K16/116—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2009305113A 2008-10-13 2009-10-13 Dengue virus neutralizing antibodies and uses thereof Ceased AU2009305113B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013202434A AU2013202434B2 (en) 2008-10-13 2013-04-04 Dengue virus neutralizing antibodies and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10491108P 2008-10-13 2008-10-13
US61/104,911 2008-10-13
PCT/IB2009/007372 WO2010043977A2 (en) 2008-10-13 2009-10-13 Dengue virus neutralizing antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013202434A Division AU2013202434B2 (en) 2008-10-13 2013-04-04 Dengue virus neutralizing antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2009305113A1 AU2009305113A1 (en) 2010-04-22
AU2009305113B2 true AU2009305113B2 (en) 2015-07-16

Family

ID=42102977

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009305113A Ceased AU2009305113B2 (en) 2008-10-13 2009-10-13 Dengue virus neutralizing antibodies and uses thereof

Country Status (10)

Country Link
US (1) US9073981B2 (enExample)
EP (1) EP2334700B1 (enExample)
JP (2) JP5814790B2 (enExample)
CN (2) CN108610416B (enExample)
AU (1) AU2009305113B2 (enExample)
BR (1) BRPI0914012B1 (enExample)
CA (1) CA2739551C (enExample)
MX (1) MX2011003588A (enExample)
NZ (1) NZ592054A (enExample)
WO (1) WO2010043977A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI464262B (zh) 2007-09-26 2014-12-11 中外製藥股份有限公司 抗體固定區的變異
SG191155A1 (en) * 2010-12-14 2013-07-31 Univ Singapore Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
PH12014500544B1 (en) * 2011-09-09 2019-03-13 Dept Of Medical Sciences Dmsc Dengue-virus serotype neutralizing antibodies
US9556254B2 (en) 2012-05-14 2017-01-31 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Cross-reactive antibodies against dengue virus and uses thereof
CA2879994C (en) 2012-08-07 2023-03-21 Massachusetts Institute Of Technology Anti-dengue virus antibodies and uses thereof
EA201591131A1 (ru) * 2012-12-13 2015-12-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Днк-конструкции антитела и способ их применения
JP7078350B2 (ja) 2013-10-28 2022-05-31 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｄｎａ抗体構築物及びその使用方法
JP6154126B2 (ja) * 2012-12-20 2017-06-28 功 宮崎 検査キットおよび検査方法
US9822166B2 (en) * 2013-03-15 2017-11-21 Dana-Farber Cancer Institute, Inc. Flavivirus neutralizing antibodies and methods of use thereof
CN103396481B (zh) * 2013-07-18 2015-06-03 华南理工大学 一种二型登革热病毒ns1蛋白的重链单域抗体及其制备方法和应用
US10087240B2 (en) * 2013-12-13 2018-10-02 Inovio Pharmaceuticals, Inc. DNA antibody constructs and method of using same
WO2015095511A2 (en) * 2013-12-20 2015-06-25 The Scripps Research Institute Functional antibodies that modulate cell death and related methods
BR112016017764A2 (pt) 2014-02-11 2017-10-10 Massachusetts Inst Technology anticorpo antidengue de amplo espectro
ES2900749T3 (es) 2014-02-11 2022-03-18 Visterra Inc Moléculas de anticuerpos contra el virus del dengue y usos de las mismas
HUE053284T2 (hu) * 2014-09-01 2021-06-28 Int Centre For Genetic Engineering And Biotechnology Vakcina
EP3226892A4 (en) 2014-12-01 2018-07-18 The Trustees Of The University Of Pennsylvania Dna antibody constructs and method of using same
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
EP3271390B1 (en) * 2015-03-17 2023-09-27 Agency For Science, Technology And Research A serotype cross-reactive, dengue neutralizing antibody and uses thereof
WO2017011495A1 (en) * 2015-07-14 2017-01-19 Vanderbilt University Engineered antibodies against dengue virus
WO2017165736A1 (en) 2016-03-25 2017-09-28 Visterra, Inc. Formulation of antibody molecules to dengue virus
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
TWI769185B (zh) * 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
WO2018081755A1 (en) * 2016-10-29 2018-05-03 University Of Miami Zika virus antibodies
US11249082B2 (en) 2016-10-29 2022-02-15 University Of Miami Zika virus assay systems
CA3093729A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
KR102238183B1 (ko) 2018-05-04 2021-04-12 가톨릭대학교 산학협력단 유전자 합성을 통해 설계된 뎅기열 바이러스의 유전형 복합 ｎｓ１ 재조합 항원 및 대조군 유행성 플라비바이러스 유전형 복합 ns1 재조합 항원 풀
US11830582B2 (en) 2018-06-14 2023-11-28 University Of Miami Methods of designing novel antibody mimetics for use in detecting antigens and as therapeutic agents
WO2020078568A1 (en) 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
CN111320688B (zh) * 2018-12-17 2021-08-24 中国科学院天津工业生物技术研究所 一种黄病毒中和抗体、其制备方法及应用
KR102048812B1 (ko) * 2018-12-19 2019-11-26 주식회사 엠디헬스케어 뎅기 바이러스 ediii에 특이적으로 결합하는 dna 압타머 및 이의 용도
JP2023526469A (ja) * 2020-05-20 2023-06-21 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク ＳＡＲＳ－ＣｏＶ－２に対する強力な中和抗体、その生成および使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067567A2 (en) * 2003-01-31 2004-08-12 Novartis Ag Anti-dengue virus antibodies, compositions, methods and uses
WO2005056600A2 (en) * 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB819376A (en) 1956-10-20 1959-09-02 Colne Switchgear K & W Ltd Improvements in electro-magnetic overload units for electrical apparatus
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
US6300104B1 (en) 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
WO2004003019A2 (en) 2002-06-28 2004-01-08 Domantis Limited Immunoglobin single variant antigen-binding domains and dual-specific constructs
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
JP4782700B2 (ja) 2004-01-20 2011-09-28 カロバイオス ファーマシューティカルズ インコーポレイティッド 最低限必須な結合決定基を用いた抗体特異性の移入
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US8337854B2 (en) * 2007-04-04 2012-12-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monoclonal antibodies against dengue and other viruses with deletion in Fc region

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067567A2 (en) * 2003-01-31 2004-08-12 Novartis Ag Anti-dengue virus antibodies, compositions, methods and uses
WO2005056600A2 (en) * 2003-12-08 2005-06-23 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind or neutralize dengue virus

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHAMBERS T.J. et al., Journal of Virology, 2003, Vol. 77, pages 3655-3668 *
GONCALVEZ A. P. et al., PNAS, 2007, Vol. 104, pages 9422-9427 *
PUTTIKHUNT C. et al., Journal of Medical Virology, 2008, Vol. 80, pages 125-133 *

Also Published As

Publication number Publication date
CN108610416A (zh) 2018-10-02
NZ592054A (en) 2013-06-28
CA2739551C (en) 2019-03-05
WO2010043977A3 (en) 2010-09-30
US20120020957A1 (en) 2012-01-26
EP2334700B1 (en) 2017-09-13
CA2739551A1 (en) 2010-04-22
CN102272155A (zh) 2011-12-07
BRPI0914012B1 (pt) 2022-02-15
WO2010043977A2 (en) 2010-04-22
EP2334700A2 (en) 2011-06-22
JP2012504955A (ja) 2012-03-01
CN102272155B (zh) 2018-05-25
JP5814790B2 (ja) 2015-11-17
AU2009305113A1 (en) 2010-04-22
US9073981B2 (en) 2015-07-07
JP2016020334A (ja) 2016-02-04
MX2011003588A (es) 2011-10-14
BRPI0914012A2 (pt) 2021-02-23
CN108610416B (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
AU2009305113B2 (en) Dengue virus neutralizing antibodies and uses thereof
EP2118140B1 (en) Human cytomegalovirus neutralising antibodies and use thereof
CA2731686C (en) Neutralizing anti-influenza a virus antibodies and uses thereof
EP2303923B1 (en) Human cytomegalovirus neutralising antibodies and use thereof
US9611316B2 (en) Human cytomegalovirus neutralising antibodies and use thereof
AU2013202434B2 (en) Dengue virus neutralizing antibodies and uses thereof
HK1260890B (zh) 登革热病毒中和抗体及其用途
HK1260890A1 (zh) 登革热病毒中和抗体及其用途
HK1164898B (en) Dengue virus neutralizing antibodies and uses thereof
HK1164898A (en) Dengue virus neutralizing antibodies and uses thereof
HK1139158B (en) Human cytomegalovirus neutralising antibodies and use thereof
HK1174344B (en) Human cytomegalovirus neutralising antibodies and use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired